Want to see HK:1873 full AI Analyst Report?
1873 Stock Chart & Stats
HK$1.76
-HK$0.01(-1.20%)
At close: 4:00 PM EST
HK$1.76
-HK$0.01(-1.20%)
Day’s Range― - ―
52-Week RangeHK$1.04 - HK$3.27
Previous CloseN/A
Volume129.00K
Average Volume (3M)10.31M
Market Cap
HK$2.47B
Enterprise ValueHK$2.31B
Total Cash (Recent Filing)HK$1.13B
Total Debt (Recent Filing)HK$1.33B
Price to Earnings (P/E)10.3
Beta2.04
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.10
Shares Outstanding2,104,565,000
10 Day Avg. Volume10,852,121
30 Day Avg. Volume10,305,290
Financial Highlights & Ratios
PEG Ratio0.63
Price to Book (P/B)0.99
Price to Sales (P/S)2.28
P/FCF Ratio44.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$4.00Price Target Upside127.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.12
Revenue Forecast (FY)HK$2.17B
Bulls Say, Bears Say
Bulls Say
Improved Profitability And Stable MarginsSustained net profits and mid-30% gross margins signal structural pricing power and service economics in the CRO model. Stable operating margins around the low teens support repeatable earnings generation and help fund operations and selective reinvestment over the next 2–6 months.
Improving Leverage And Stronger Balance SheetMaterial reduction in debt-to-equity and a stronger equity base enhance financial flexibility, lower refinancing risk, and support continued investment in lab capacity and the venture portfolio. A healthier balance sheet improves resilience to industry cyclicality and funds strategic initiatives.
Diversified CRO Fee-for-service Model Plus Venture PlatformAn integrated service offering drives recurring, project-based cash flows while the venture/incubation arm offers asymmetric long-term upside via asset monetization. This diversification reduces single-revenue dependency and can smooth income while creating optionality from incubated assets.
Bears Say
Multi-year Revenue DeclineSustained top-line contraction undermines the CRO's operating leverage: lower project volumes make it harder to scale fixed lab capacity and sustain staffing. Continued revenue declines would threaten long-term margin sustainability and constrain growth funding.
Weakening Operating And Free Cash Flow MomentumA sharp drop in free cash flow reduces internal funding for capex, capacity and venture investments, increasing dependence on external financing. Persistently weaker cash conversion heightens execution risk and limits the firm's ability to absorb project timing swings.
Historical Profitability VolatilityPrior swings between losses and profits indicate sensitivity to project mix and demand. If recent profit levels are not sustained, leverage and credit metrics could deteriorate rapidly, constraining strategic plans and increasing refinancing or liquidity risks.
Viva Biotech Holdings News
1873 FAQ
What was Viva Biotech Holdings’s price range in the past 12 months?
Viva Biotech Holdings lowest stock price was HK$1.04 and its highest was HK$3.27 in the past 12 months.
What is Viva Biotech Holdings’s market cap?
Viva Biotech Holdings’s market cap is HK$2.47B.
When is Viva Biotech Holdings’s upcoming earnings report date?
Viva Biotech Holdings’s upcoming earnings report date is Aug 31, 2026 which is in 58 days.
How were Viva Biotech Holdings’s earnings last quarter?
Viva Biotech Holdings released its earnings results on Mar 30, 2026. The company reported HK$0.051 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.051.
Is Viva Biotech Holdings overvalued?
According to Wall Street analysts Viva Biotech Holdings’s price is currently Undervalued.
Does Viva Biotech Holdings pay dividends?
Viva Biotech Holdings pays a Notavailable dividend of HK$0.01 which represents an annual dividend yield of N/A. See more information on Viva Biotech Holdings dividends here
What is Viva Biotech Holdings’s EPS estimate?
Viva Biotech Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Viva Biotech Holdings have?
Viva Biotech Holdings has 2,104,565,000 shares outstanding.
What happened to Viva Biotech Holdings’s price movement after its last earnings report?
Viva Biotech Holdings reported an EPS of HK$0.051 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -4.785%.
Which hedge fund is a major shareholder of Viva Biotech Holdings?
Currently, no hedge funds are holding shares in HK:1873
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Viva Biotech Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
177.01%
12-Months-Change
Fundamentals
Return on Equity
5.57%
Trailing 12-Months
Asset Growth
6.87%
Trailing 12-Months
Company Description
Viva Biotech Holdings
Viva Biotech Holdings, founded in 2008 and based in Shanghai, China, operates as an investment holding company primarily dedicated to providing comprehensive, structure-based drug discovery services to biotechnology and pharmaceutical clients worldwide. Its extensive discovery biology offerings encompass protein expression and purification, structural biology, hit identification, bioassay development, biomolecular interaction analysis, and pharmacokinetic studies. The company also delivers a suite of chemistry services, including medicinal and synthetic chemistry, analytical services, preparative purification, and computer-aided drug design, all supported by robust chemical technology platforms. Viva Biotech further specializes in antibody drug research and development, covering antigen preparation, multi-species antibody discovery, monoclonal antibody production, functional screening and characterization, antibody engineering, and cell line engineering. This work is facilitated by cutting-edge technological platforms such as hybridoma, phage and yeast display, mammalian display, VHH antibody technology, high-throughput sequencing, computer-aided drug design, HDX-MS, protein crystal structure determination, and SPR technology. Beyond its core service offerings, Viva Biotech provides various biological resources, including cell lines, crystal structures, GPCR proteins, antibodies, and other purified proteins. The company also offers contract development and manufacturing (CDMO) services for small molecule active pharmaceutical ingredients (APIs) and their intermediates. Furthermore, it engages in the trading of APIs, intermediates, and formulations, and operates under an "equity for service" model. Additional services include general research, laboratory facility rentals, project management and bidding assistance, and the sale of chemical compounds.
1873 Stock 12 Month Forecast
Average Price Target
HK$4.00
▲(127.27% Upside)
Technical Analysis
Genscript Biotech
―
Wuxi Biologics (Cayman)
―
Pharmaron Beijing Co., Ltd. Class H
―
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
―
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
―
Options Prices
Currently, No data available
---